5.94
-0.23(-3.73%)
Currency In USD
| Previous Close | 6.17 |
| Open | 6.17 |
| Day High | 6.26 |
| Day Low | 5.84 |
| 52-Week High | 12.36 |
| 52-Week Low | 5.6 |
| Volume | 12.29M |
| Average Volume | 23.56M |
| Market Cap | 2.35B |
| PE | -3.51 |
| EPS | -1.69 |
| Moving Average 50 Days | 7.5 |
| Moving Average 200 Days | 7.31 |
| Change | -0.23 |
If you invested $1000 in Recursion Pharmaceuticals, Inc. (RXRX) since IPO date, it would be worth $189.78 as of March 14, 2025 at a share price of $5.94. Whereas If you bought $1000 worth of Recursion Pharmaceuticals, Inc. (RXRX) shares 3 years ago, it would be worth $964.29 as of March 14, 2025 at a share price of $5.94.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th
GlobeNewswire Inc.
Feb 24, 2025 1:00 PM GMT
Company to host public (L)earnings call on February 28th at 8:30 am ET / 6:30 am MT / 1:30 pm GMTSalt Lake City, UT, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrial
Altitude Lab Launches Pre-seed Venture Fund, Anchored by Recursion CEO Chris Gibson, Enabling SBIR-awarded Biotechs Hit by Funding Gap to Build in Salt Lake City
GlobeNewswire Inc.
Feb 19, 2025 2:00 PM GMT
The Altitude Lab Fund aims to deliver strong returns to Limited Partners, accelerate the growth of Salt Lake City’s Life Science hub, and enable high potential startups support while federal funding is stalledSALT LAKE CITY, Feb. 19, 2025 (GLOBE NE
Altitude Lab Startups Raise $154M in Capital
GlobeNewswire Inc.
Feb 18, 2025 4:00 PM GMT
The Accelerator Awards $150,000 Fellowship to Elnora AI CEO, and Announces Key Cohort MilestonesSALT LAKE CITY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Today, Altitude Lab announced that its incubating startups have collectively raised $154 million in ea